Analytical Data
-
Gene name
Claudin-6/CLDN6 Protein-VLP
- Application
-
Alternative Names
Claudin-6; Skullin; CLDN6; Claudin6; Skullin 2
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56747
-
Expression Region
M1-V220
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-6 (CLDN6) is a member of the claudin family of tight junction proteins that play a critical role in maintaining the integrity of cell barriers. Its expression is notably high in various types of epithelial tissues and is often upregulated in certain cancers, making it a potential target for therapeutic interventions and vaccine development. Research into CLDN6 has garnered attention due to its ability to modulate paracellular permeability and its involvement in cell signaling pathways. The development of CLDN6 protein-based virus-like particles (VLPs) represents an innovative approach to harnessing the immunogenic properties of this protein for applications in immunotherapy and vaccine strategies. These VLPs can effectively mimic the structure of viruses, providing a platform for displaying CLDN6, which may enhance the immune response against CLDN6-expressing tumors. This approach is particularly promising in the context of cancer vaccines, where targeting tumor-specific antigens can stimulate robust immune responses while minimizing off-target effects. The ongoing research into CLDN6/CLDN6 VLP recombinant proteins aims to elucidate their potential as powerful tools for both therapeutic development and basic scientific insights into cellular functions and interactions in pathological conditions.
